The secret lies in rigorous characterization

Antibody-drug conjugates (ADCs) are powerful anti-cancer agents with growing variety and sophistication that presents challenges in quality control and product characterization. KBI Biopharma is a global CDMO with expertise in ADC characterization, having established an array of methods to determine critical structural components. KBI also assists clients in developing regulatory paperwork, maintaining data integrity, and employing cutting-edge analytic techniques to reduce potential pharmaceutical manufacturing setbacks. The burgeoning diversity of ADCs makes this comprehensive oversight approach vital in mitigating development delays and securing regulatory approval.